Cell & Gene Therapy Debate: Intrinsic Editing vs Systemic Combination

12/27/20 • 22 min

In this podcast first recorded at the 2020 IO360° Summit, Dr Aiman Shalabi, GSK, moderated a cell and gene therapy debate on intrinsic editing vs systemic combination Participants included: Mark O’Hara, MD, University of PennsylvaniaSaul Priceman, PhD, City of Hope To learn more about the upcoming IO360° 2021 Summit please visit www.io360summit.com

Previous Episode

Operational Dynamics of Implementing & Managing Basket Trials

In this podcast, first recorded at the IO360° 2020 Summit, Dr Millie Schultz, Seattle Genetics, discusses operational dynamics of implementing and managing basket trials. Discussion points include: What are the operational complexities of basket trials? How do they differ from standard IO trials?How do you identify the right institutions who can handle basket trials? What goes into that decision making?How do you set up your protocol in an open ended way so that you can add a cohort or make adjustments based on signals you received?How do you set up your database to be able to manage all the different tumor types and different types of case port forms. To learn more about the upcoming IO360° 2021 Summit please visit www.io360summit.com

Next Episode

HLA Loss and the Impact on Immunotherapy

Loss of the HLA locus impairs presentation of tumor antigens and is frequently found in advanced cancers. This talk presented by Dr Lee Albacker, Foundation Medicine and first recorded at the 2020 IO360° Summit, will describe the landscape of HLA loss and other response biomarkers in a dataset of 90,000 solid tumor samples and highlight the effect of HLA loss on checkpoint inhibitor response. To learn more about the upcoming IO360° 2021 Summit please visit www.io360summit.com